PATENT CLAIM ANALYSIS

Application Number: 16069546
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "001890"]

Abstract:
Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.

Claim (Index 52):
The radiolabeled compound of  claim 49 , wherein Q is represented by (CR\u2032R\u2033)nX,\n wherein R\u2032 and R\u2033 are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroalicyclic, heteroaryl, alkoxy, aryloxy, thioalkoxy, thioaryloxy, hydroxyl, halogen, trihaloalkyl, trihaloalkoxy, amine, cyano, nitro, carbonyl, thiocarbonyl, carboxylate, thioacarboxylate, amide, thioamide, carbamate, thiocarbamate, alkaryl, aralkyl, sulfinyl, sylfonyl, sulfonate, and sulfonamide; n is an integer of from 1 to 20; and X is said radioactive halogen.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 1.38889
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11714760', '10659747', '12449129', '14023681', '12631116']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.4786639166653663
- 35 USC 102 Novelty (BERT): 0.5168679876514586
- Combined Prediction Score: 0.4824843237639755
- Mean Citation Score: 235.110082
- Max Citation Score: 283.49173
- Similarity Product: 198.8977175795853

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test